0001209191-22-024919.txt : 20220420 0001209191-22-024919.hdr.sgml : 20220420 20220420160529 ACCESSION NUMBER: 0001209191-22-024919 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220419 FILED AS OF DATE: 20220420 DATE AS OF CHANGE: 20220420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hopfner Robert Lorne CENTRAL INDEX KEY: 0001551966 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 22838053 MAIL ADDRESS: STREET 1: C/O BAY CITY CAPITAL, LLC STREET 2: 750 BATTERY STREET, SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-19 0 0001693011 Inozyme Pharma, Inc. INZY 0001551966 Hopfner Robert Lorne C/O INOZYME PHARMA, INC. 321 SUMMER STREET SUITE 400 BOSTON MA 02210 1 0 0 0 Common Stock 2022-04-19 4 P 0 1070000 3.69 A 2661154 I By Pivotal bioVenture Partners Fund I, L.P. The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Mr. Kin Ho Kwok, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein. /s/ Axel Bolte, as attorney-in-fact for Robert Hopfner 2022-04-20